Icon

Jentadueto XR - (2.5 mg/1000 mg, 5 mg/1000 mg; Tablet ER)

Linagliptin and Metformin Hydrochloride Boehringer Ingelheim
2.5 mg/1000 mg, 5 mg/1000 mg; Tablet ER
Less Than $1000 mn
None None
More Than 5
Less Than 5
None None
Jentadueto XR (linagliptin and metformin hydrochloride extended-release) is a dipeptidyl peptidase-4 (DPP-4) inhibitor and biguanide combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate.
Yes
* **** ** ***** ** ******* *******, *** *** ******* ** *** ******* *** *******. ********* ** *** ******, ********** ** ** ********* ** * ******** ****** (****) ** ***. **, **** ** *** ******** *** ****** *** ******* ****** ****. ** ******* *** **** ********* ** ***.
Jentadueto XR Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11
*** **** *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** *********
*** ****** *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** *********
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
*** **** *** \ ** -**- *** ********* ********* ******** ***** *** **** (******** ******)
*** ****** ** \ ** -**- *** ********* ********* ******** ***** *** **** (******** ******)
  1. *** **, **** : * ****-** ** ***** *** ***** ** *** *** *******.
  2. *** *, **** : *** **** ******** ********* ******** *** *** *** *********.
  3. *** **, **** : *** ****** ******** ********* ******** *** *** *** *********.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.